A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone MetastasesRichard J. Lee, Matthew R. Smith, Malgorzata E. Smas et al.|Clinical Cancer Research|2013Cited by 74
Investigator-sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases.Richard J. Lee, Matthew R. Smith, M. Dror Michaelson et al.|Journal of Clinical Oncology|2012Cited by 2